What if we could take the guesswork out of cancer treatment—and move from try and hope to test and know?

In this episode of Med Tech Gurus, we sit down with Jim Foote, CEO and Founder of First Ascent Biomedical, whose mission began after losing his son to cancer. That experience became the driving force behind Functional Precision Medicine (FPM)—a groundbreaking approach that combines tumor testing, genomics, and AI to rank the most effective drugs for each patient in just ten days

Backed by a Nature Medicine study showing an 83% patient benefit rate, First Ascent is proving that personalization saves lives. With automation reducing lab times from hours to minutes and new CLIA-certified labs accelerating access, Jim and his team are reshaping how cancer care is delivered.

From building trust with clinicians to leading through loss, Jim shares a powerful story of innovation, resilience, and purpose that every medtech leader can learn from.

What if trauma care didn't require a full surgical team or a giant toolbox to save lives in critical moments? In this episode of Med Tech Gurus, Dr. Adam Power, vascular surgeon and co-founder of Frontline Medical Technologies, takes us inside the development of the COBRA-OS—an ultra-simplified REBOA device that's transforming trauma care.

From war zones to rural communities, Dr. Power explains how miniaturization and smart design make this innovation faster, safer, and more accessible—without sacrificing patient outcomes. We discuss the challenges of commercialization, academic innovation, and the evolving role of physicians as entrepreneurs. Gurus, this episode is a masterclass in turning front-line insight into global impact. Don't miss it!

What if the missing link in treating autoimmune disease wasn't a new drug—but a better way to measure stress?

In this episode of Med Tech Gurus, we sit down with Dr. Andrew Holman, CEO of Inmedix and the innovator behind CloudHRV, the first FDA-cleared platform to measure stress biology with medical-grade precision

.At a time when 75% of autoimmune treatments fail—costing billions and leaving patients without answers—CloudHRV delivers actionable insights in just five minutes reframing how clinicians think about chronic disease.

Dr. Holman takes us inside his two-decade journey building Inmedix, from early IP strategy to securing partnerships with global pharma. Along the way, he shares lessons on leveraging licensing as a growth strategy, building a culture of innovation, and aligning science, business, and patient care in the pursuit of transformative healthcare solutions.

Whether you're a founder, investor, or clinician, this conversation will reshape how you think about precision medicine and the future of patient-centered innovation.